{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=30+-+15",
    "query": {
      "intervention": "30 - 15"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 3585,
    "total_pages": 359,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=30+-+15&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T12:27:27.518Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07588698",
      "title": "Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin's B-cell Lymphoma",
        "Lymphoma Non-Hodgkin",
        "Diffuse Large B-Cell Lymphoma (DLBCL)"
      ],
      "interventions": [
        {
          "name": "Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP)",
          "type": "DRUG"
        },
        {
          "name": "Epcoritamab",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography (PET)",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood specimen collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaires",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Computerized tomography (CT)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BEHAVIORAL"
      ],
      "sponsor": "Carrie Ho, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-09-15",
      "completion_date": "2029-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-09-04T12:27:27.518Z",
      "location_count": 2,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07588698"
    },
    {
      "nct_id": "NCT07088406",
      "title": "A Multi-level Mother-daughter Physical Activity Intervention for Pre- Adolescent Latinas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Physical Activity",
        "Family Communication",
        "Parenting Behavior"
      ],
      "interventions": [
        {
          "name": "Physical Activity Promotion",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Healthy Eating",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "San Diego State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "8 Years to 65 Years · Female only"
      },
      "enrollment_count": 432,
      "start_date": "2025-08-21",
      "completion_date": "2029-08-31",
      "has_results": false,
      "last_update_posted_date": "2025-09-30",
      "last_synced_at": "2026-09-04T12:27:27.518Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07088406"
    },
    {
      "nct_id": "NCT00075504",
      "title": "Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage II Gallbladder Cancer",
        "Stage IIIA Gallbladder Cancer",
        "Stage IIIB Gallbladder Cancer",
        "Stage IVA Gallbladder Cancer",
        "Stage IVB Gallbladder Cancer"
      ],
      "interventions": [
        {
          "name": "triapine",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2003-11",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2015-09-28",
      "last_synced_at": "2026-09-04T12:27:27.518Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00075504"
    },
    {
      "nct_id": "NCT03410225",
      "title": "Motivational Interviewing for Getting Healthy TodaY Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pregnancy Related",
        "Diet Modification"
      ],
      "interventions": [
        {
          "name": "CAMI-TPP",
          "type": "BEHAVIORAL"
        },
        {
          "name": "CAMI-Fitness",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "24 Years",
        "sex": "MALE",
        "summary": "15 Years to 24 Years · Male only"
      },
      "enrollment_count": 26,
      "start_date": "2019-06-01",
      "completion_date": "2019-08-28",
      "has_results": false,
      "last_update_posted_date": "2019-10-15",
      "last_synced_at": "2026-09-04T12:27:27.518Z",
      "location_count": 3,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03410225"
    },
    {
      "nct_id": "NCT04856189",
      "title": "Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Urothelial Carcinoma",
        "Locally Advanced Urothelial Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Refractory Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Selinexor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mamta Parikh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2021-04-08",
      "completion_date": "2024-02-13",
      "has_results": true,
      "last_update_posted_date": "2026-01-29",
      "last_synced_at": "2026-09-04T12:27:27.518Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04856189"
    },
    {
      "nct_id": "NCT07256652",
      "title": "How Does YES Bar Affect Blood Glucose Levels?",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Blood Glucose Monitoring"
      ],
      "interventions": [
        {
          "name": "YES Bar",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Efforia, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 23,
      "start_date": "2025-11-25",
      "completion_date": "2026-04-25",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-09-04T12:27:27.518Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07256652"
    },
    {
      "nct_id": "NCT02451748",
      "title": "IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Lab Work",
          "type": "OTHER"
        },
        {
          "name": "Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)",
          "type": "DRUG"
        },
        {
          "name": "Certolizumab pegol (CDP870, tradename Cimzia)",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Sulfasalazine",
          "type": "DRUG"
        },
        {
          "name": "Medrol",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Triamcinolone",
          "type": "DRUG"
        },
        {
          "name": "Naproxen",
          "type": "DRUG"
        },
        {
          "name": "Leflunomide",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "humira",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2015-08",
      "completion_date": "2017-12",
      "has_results": true,
      "last_update_posted_date": "2024-07-10",
      "last_synced_at": "2026-09-04T12:27:27.518Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02451748"
    },
    {
      "nct_id": "NCT02123017",
      "title": "Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colonoscopy Preparation"
      ],
      "interventions": [
        {
          "name": "90 grams of Crystalline Lactulose",
          "type": "DRUG"
        },
        {
          "name": "135 grams of Crystalline Lactulose",
          "type": "DRUG"
        },
        {
          "name": "180 grams of Crystalline Lactulose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2014-04",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2016-02-24",
      "last_synced_at": "2026-09-04T12:27:27.518Z",
      "location_count": 1,
      "location_summary": "Chattanooga, Tennessee",
      "locations": [
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02123017"
    },
    {
      "nct_id": "NCT04191616",
      "title": "Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsed or Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 54,
      "start_date": "2020-08-06",
      "completion_date": "2024-10-01",
      "has_results": true,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-09-04T12:27:27.518Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Denver, Colorado • New Haven, Connecticut + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago Ridge",
          "state": "Illinois"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04191616"
    },
    {
      "nct_id": "NCT03380078",
      "title": "Translating Evidence-based Interventions for ASD: Multi-Level Implementation Strategy",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Teams Leadership Institute (TLI)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Motivational Enhancement (TIPS for Training)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Classroom Pivotal Response Teaching (CPRT)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "An Individualized Mental Health Intervention for ASD (AIM HI)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Team-Enhanced Teams Leadership Institute (TLI)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1206,
      "start_date": "2017-10-20",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-05",
      "last_synced_at": "2026-09-04T12:27:27.518Z",
      "location_count": 3,
      "location_summary": "Sacramento, California • San Diego, California • Westwood, Los Angeles, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Westwood, Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03380078"
    }
  ]
}